Adoptive Macrophage Transfers for Nanoparticle Delivery

用于纳米颗粒递送的过继巨噬细胞转移

基本信息

  • 批准号:
    10794553
  • 负责人:
  • 金额:
    $ 18.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2027-06-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT Immune cells will serve as next-generation vehicles to deliver cargo such as bioactive drugs and contrast agents to inflamed tissues. Due to their abundant expression of chemokine receptors, cells like macrophages have the capacity to infiltrate inflamed tissues with remarkable specificity. Researchers are exploiting this capability to direct the transport of attached nanoparticles containing drugs and other cargo to diseased tissues (e.g., from cancer, infectious diseases, autoimmune disorders, and cardiovascular disease). However, macrophages are living entities that can change their function in complex and sometimes unexpected ways when loaded with nanoparticles. Thus, there is a fundamental need to understand the interactions between macrophages and the nanoparticles they carry. To address this gap in knowledge, my laboratory will investigate two focus areas. First, we will study how the physical properties of nanoparticles affect macrophage phenotypes. Using nanofabrication, we will create nanoparticles that vary in size, shape, stiffness, and composition; direct their attachment onto, or internalization within, macrophages; and measure their responses using epigenomic, transcriptomic, and molecular phenotyping tools. This focus area will reveal differentially expressed genes that are involved in the macrophage responses to nanoparticle loadings of various design. In the second focus area, we will study the principal factors that govern cell-mediated transport of nanoparticles to inflamed tissues. Different macrophage- nanoparticle complexes will be made and injected into mice harboring different models of inflammation designed to recruit different subpopulations of immune cells. We will study the role of nanoparticle placement (i.e., onto the surfaces of cells versus within their interiors) as well as the role of macrophage phenotypes on their transport efficiency to inflamed tissues. The outcome of this work will be a set of design rules that predict macrophage- mediated transport of nanoparticles to inflamed tissues. Once established, these rules will be exploited to guide the design of new types of nanoparticles that interface with macrophages, promote specific phenotypes that are advantageous for specific treatments, and facilitate improved transport to those diseased sites. Such a capability will improve clinical efforts to use adoptively transferred macrophages to deliver drugs, vaccines, and contrast agents for a range of inflammatory diseases.
摘要

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Systemic Tumor Suppression via Macrophage-Driven Automated Homing of Metal-Phenolic-Gated Nanosponges for Metastatic Melanoma.
  • DOI:
    10.1002/advs.202207488
  • 发表时间:
    2023-06
  • 期刊:
  • 影响因子:
    15.1
  • 作者:
    Liao, Xue;Gong, Guidong;Dai, Mengyuan;Xiang, Zhenyu;Pan, Jiezhou;He, Xianglian;Shang, Jiaojiao;Blocki, Anna Maria;Zhao, Zongmin;Shields IV, C. Wyatt;Guo, Junling
  • 通讯作者:
    Guo, Junling
Microrobots for Biomedicine: Unsolved Challenges and Opportunities for Translation
  • DOI:
    10.1021/acsnano.3c03723
  • 发表时间:
    2023-07-26
  • 期刊:
  • 影响因子:
    17.1
  • 作者:
    Lee, Jin Gyun;Raj, Ritu R.;Shields, C. Wyatt
  • 通讯作者:
    Shields, C. Wyatt
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Charles Wyatt Shields IV其他文献

Charles Wyatt Shields IV的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Charles Wyatt Shields IV', 18)}}的其他基金

Adoptive Macrophage Transfers for Nanoparticle Delivery
用于纳米颗粒递送的过继巨噬细胞转移
  • 批准号:
    10501313
  • 财政年份:
    2022
  • 资助金额:
    $ 18.06万
  • 项目类别:
Adoptive Macrophage Transfers for Nanoparticle Delivery
用于纳米颗粒递送的过继巨噬细胞转移
  • 批准号:
    10688187
  • 财政年份:
    2022
  • 资助金额:
    $ 18.06万
  • 项目类别:
Acoustofluidic Pipette for Rapid Serodiagnosis of Candida Infection
用于念珠菌感染快速血清诊断的声流控移液器
  • 批准号:
    10388272
  • 财政年份:
    2021
  • 资助金额:
    $ 18.06万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 18.06万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 18.06万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 18.06万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 18.06万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 18.06万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 18.06万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 18.06万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 18.06万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了